Popular on eTradeWire
- Roasters Coffee - Community Giving Day December 31st, 2018 181
- Apex Officer Showcasing Latest Virtual Reality Police Training Innovation at CES 2019 161
- Homestake Capital teams up with CCB Foundation to make bike racing an educational experience 152
- NCRF Proudly Announces the 20th Annual Black College Expo Giving Millions in Scholarships On Site 151
- Author & Motivational Specialist Stephanie C. White was a Keynote Speaker at the Wow Wedding Expo 149
- Kemet Educational Services launches Holiday STEM Online Course 121
- Actor and MTv show host Nick Cannon pays it forward
- The Fastest Way To Build The Boarder Wall In 2019: Jose Franco For US President 2020
- Easy to Build Network by BUSYZ
- Steve Dalton Wes Wilt Being Investigated
Similar on eTradeWire
- Caspase-3 Activity Assay Kit II (Fluorometric)
- Smarteeva Unveils New Executive Advisory Board, Welcomes New Members
- Pulse Therapeutics and ICHOR Vascular Merge to Form Euphrates Vascular
- RNA Search Inc Announces Expansion of Recruiting Services Into New Industries
- OncoBeta® GmbH is listed as one of the Top 20 MedTech Outlook Solution Providers in Europe
- Bioquark Inc and Ectocrine Technologies LLC to Collaborate on Mosquito-Derived Health Product Develo
- Chemic Laboratories Inc.and Arihant Innochem Pvt. Ltd India Announce Joint Cooper
- 3D Printing Positioned to Address Issues Preventing Wide Adoption of Microneedle Drug Delive
- Forrester Names 360insights a Channel Technology Leader
- TRIGR Therapeutics to Present at Biotech Showcase™ During JP Morgan Healthcare Conference, San Francisco, January 2019
Rupali Verma, the principal analyst, stated, "Close to 45% of the subcutaneously administrable biologics are monoclonal antibodies; these are followed by other types of protein-based therapeutics, including interferons, interleukins, hormones, enzymes and cytokines. Further, even certain vaccines, recombinant peptides and cell / gene therapies are other therapy types being evaluated for subcutaneous delivery. Moreover, ongoing technical advances have led to the development of innovative technology platforms designed to enable the delivery of highly viscous formulations as well."
The report presents opinions on several key aspects of the market. Among other elements, it includes:
1. A detailed assessment of the current market landscape of commercially available biologics that are designed for delivery via the subcutaneous route, along with information on the developer(s), type of molecule, target indication / therapeutic area, approval year, dose strength, treatment regimen and available dosage forms. The study also includes comprehensive case studies on leading subcutaneous biologics, featuring details on annual sales, mechanisms of action, development histories, technology platforms (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).
2. An in-depth analysis of the various subcutaneous biologics that are currently under clinical development, with information on the developer(s), phase of development, type of molecule, and target therapeutic area.
3. A review of various innovative technology platforms that are used for the formulation of drugs for subcutaneous delivery, highlighting their key features and providing information on their developers, mechanisms of action and advantages. The study also includes an insightful three-dimensional analysis of the technology platforms that are presently engaged in developing drug formulations for subcutaneous delivery, comparing them based on pipeline strength (in terms of marketed / under development drugs based on the technology), supplier power (in terms of year of establishment and size of employee base) of the developer and a number of collaborations established related to the technology.
More on eTradeWire News
- Pallett Valo expands its international connectivity by joining Geneva Group International (GGI)
- Pure Depello LLC, Officially Shutters Colorado and Arizona Business and Dissolves
- Innocent Lives Foundation hires Shane McCombs as COO and adds Robin Dreeke, former head of FBI Behavioral Analysis Program, to Board of Directors
- Allied Wallet Listed as a Key Player in $33.25 Billion Payment Gateway Market
- Medic-CE Boosts Fire Continuing Education Training with Clarion UX Fire & Rescue Group Partnership
- "There Is No Here" by Jeremy Orlando is published
- SUSIE CASTELLINI JOINS Berkshire Hathaway HomeServices Hilton Head Bluffton Realty
4. A detailed benchmark analysis of technology providers that are based in North America and Europe, highlighting the advantage(s) of their proprietary technology platforms, applicability to other types of molecules, and other possible modes of drug delivery.
5. Elaborate profiles of key technology providers, featuring an overview of the companies, a review of their proprietary technologies, mechanisms of action, key advantages, list of product candidates developed using the technology, recent developments related to the technology (funding and collaborations) and a comprehensive future outlook.
6. In-depth review of the most advanced and popular subcutaneous drug delivery systems, focused on large volume wearable injectors, autoinjectors, pen injectors, needle free injectors, prefilled syringes, drug reconstitution systems and implants, providing information on their developer(s) and device specifications / features. Details of specific parameters captured for different device categories are mentioned as follows:
7. Large volume wearable injectors: Type of device (infusion pump and patch pump), type of dose delivered (continuous and bolus), volume of drug container / storage capacity (in mL), usability (disposable and reusable) and stage of development (commercialized and under development).
8. Autoinjectors: Type of drug container (syringe, cartridge and others), usability (disposable and reusable), mechanism of action (automatic, semi-automatic and manual), volume of the drug container (in mL) and dosage type (fixed dose and variable dose).
9. Pen injectors: Usability (disposable and reusable), volume of the drug container (in mL) and dosage type (fixed dose and variable dose).
10. Needle free injection systems: Type of technology (jet, spring and gas), usability (disposable and reusable) and drug volume delivered (in mL).
11. Prefilled syringes: Type of syringe (glass and plastic).
12. Drug reconstitution systems: Type of device (dual chambered systems and other novel systems), type of container (cartridge and others) and usability (disposable and reusable).
13. Implants: Type of material (silicone, titanium, polymers and others), target therapeutic indication, type of implant (biodegradable and non-biodegradable), treatment duration, type of drug delivered, dose strength and stage of development.
More on eTradeWire News
- Detectamet, Pocklington based detectable products manufacturer, appoint new Sales Manager
- Wrights GPX announce 'Cost Price POS Clearance' for Trade Customers
- Miss America's Ugly Daughter: Bess Myerson & Me
- Wrights GPX announces January Slatwall stock clearance
- Small Businesses Become More Productive in 2019 With ezAccounting Software From Halfpricesoft.com
- Jacob Tolliver Brings Unique Story to Mainstage Theater at Pheasant Run
- International Keynote Speaker Christina Aldan Nominated for 2019 Best Motivational Speaker/Coach
14. A comprehensive product competitiveness analysis of large volume wearable injectors and subcutaneous autoinjectors taking into consideration the supplier power (based on size of employee base) and product specifications.
A discussion on affiliated trends, key drivers and challenges, under a SWOT framework. The analysis features a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall subcutaneous products market.
Verma further added, "Despite the various limitations associated with subcutaneous formulations, the field offers immense opportunities to pharmaceutical companies, device manufacturers and technology developers. Companies are also reformulating their intravenous drugs for subcutaneous administration for life cycle management and product differentiation purposes. The rising incidence of chronic clinical conditions (which are characterized by the need for frequent administration of medications) and continuous efforts of therapy / device developers in this field are anticipated to drive the growth in this market in the coming years."
The research covers detailed profiles and assesses product portfolios of the following companies:
2. Ajinomoto Althea
4. Ascendis Pharma
5. Avadel Pharmaceuticals
7. Halozyme Therapeutics
9. Xeris Pharmaceuticals
10. Serina Therapeutics
For additional details, please visit
or email firstname.lastname@example.org
- New Injection Molded, Waterproof Custom iMac Case Coming Soon from SKB Cases
- Sun Acquisitions has been engaged to sell a knife and blade fabricator
- Spark Design Awards Announced At Winners Celebration
- Phase 4 site work now underway at Nobility Crest at Ocean Township
- Two Banking Professionals Join the Boys & Girls Club Board of Directors
- CDL drug test requirements begin prior to employment
- National Marriage Week (February 7-14)
- Top Locations for Viewing Cherry Blossoms in Japan North of Tokyo
- Agency on Aging Northeastern Illinois to Host Advocacy Breakfast for Older Adults and Caregivers
- Dental hygiene for kids begins with teaching them at a young age
- Wood Palace Kitchens to host "Health Kick in the Kitchen" on Jan. 23rd
- Voluntary Disclosure Program; CRA that can either save you or destroy you!
- Laptop Parts Website In Full Swing
- Hard bridge sleeves from MECA provide imprint flexibility
- South Shore Habitat for Humanity names Michael Burman as Director of Finance and Administration
- Collaborations Beers with Georgetown Brewing to Headline Chinese New Year at Lucky Envelo
- Keri Systems Inc. Welcomes Northeast Regional Sales Manager
- Tech startup Surf launches rideshare entertainment tablets in Dallas
- United Premier Soccer League Announces Santa Monica United FC as SoCal Expansion Team
- Lambs Farm Breaks Holiday Record